Treatment for atrophic macular degeneration

Current Opinion in Ophthalmology

Volumn 22, Issue 3, 2011, Pages 190-193

  Meleth, Annal D ^a   Wong, Wai T ^a   Chew, Emily Y ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

age related macular degeneration; atrophic macular degeneration; geographic atrophy; retina; retinal pigment epithelium

Indexed keywords

ACU 4429; AGENTS ACTING ON THE EYE; AL 8309 A; ANTIOXIDANT; ARC 1905; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; CORTICOSTEROID; DOCOSAHEXAENOIC ACID; ECULIZUMAB; FCFD 4514 S; FENRETINIDE; FLUOCINOLONE ACETONIDE; ICOSAPENTAENOIC ACID; ILLUVIEN; IMMUNOLOGIC AGENT; NOVADUR; OMEGA 3 FATTY ACID; OT 551; PLACEBO; RAPAMYCIN; RNA 144101; SEROTONIN AGONIST; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN;

ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG MEGADOSE; GEOGRAPHIC ATROPHY; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; GEOGRAPHIC ATROPHY; HUMANS; MACULAR DEGENERATION; RETINA; RETINAL PIGMENT EPITHELIUM;

EID: 79955053610     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834594b0     Document Type: Article

References (29)

1. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009; 127:533-540.
2. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010; 30:1350-1367.
3. Fleckenstein M, Adrion C, Schmitz-Valckenberg S, et al. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010; 51:637-642.
4. Meleth AD,Mettu P, Agron E, et al. Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry. Invest Ophthalmol Vis Sci 2010 (Epub ahead of print).
5. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci 2010; 51:6131-6139.
6. OMEGA. http://clinicaltrials.gov/ct2/show/NCT00485394?term= ot+551&rank=1. [Accessed 31 March 2008]
7. Collier RJ, Patel Y, Martin EA, et al. Agonists at the serotonin receptor (5HT1A) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci 2010 [Epub ahead of print].
8. GATE Study.http://www.clinicaltrials.gov/ct2/show/NCT00890097?term= AMD+and+GATE+and+Alcon&rank=1. [Accessed 7 December 2009]
9. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005; 46:4393-4401. (Pubitemid 44264531)
10. Fenretinide. http://www.clinicaltrials.gov/ct2/show/NCT00429936?term=- fenretinide+and+AMD&rank=1 [Accessed 21 July 2010]
11. RY K. Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ACU-4429 in subjects with geographic atrophy. http://clinical trials.gov/ct2/show/NCT01002950?term=acu+4429&rank=1 [Accessed 1 December 2010]
12. Nussenblatt RB, Ferris F 3rd. Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 2007; 144: 618-626.
13. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in agerelated macular degeneration (AMD) treatment. Eye (Lond) 2011; 25:126-139.
14. Illuvien. http://clinicaltrials.gov/ct2/show/NCT00695318?term= alimera&rank=2. [Accessed 2 June 2008]
15. Nussenblatt RB, Byrnes G, Sen N, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 30:1579-1587.
16. SIRGA.http://clinicaltrials.gov/ct2/show/NCT00766649?term=sirolimus+ geographic+atrophy&rank=1. [Accessed 17 September 2010]
17. Charbel Issa P, Victor Chong N, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration: current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2011; 249:163-174.
18. Eculizumab. http://clinicaltrials.gov/ct2/show/NCT00935883?term=eculizu mab&rank=4. [Accessed 21 July 2009]
19. FCFD4514S. A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy. http://clinicaltrials.gov/ct2/show/NCT01229215?term= geographic+atrophy&rank=2. [Accessed 19 May 2010]
20. Cho Y, Wang JJ, Chew EY, et al. Toll-like receptor polymorphisms and agerelated macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci 2009; 50:5614-5618.
21. Klein ML, Ferris FL, Francis PJ, et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010; 117:1554-1559; 1559 e1551.
22. Ambati J. A phase I open label dose escalation trial of RNA-144101 in the treatment of geographic atrophy. http://clinicaltrials.gov/ct2/show/ NCT01093170?term=geographic+atrophy+ambati&rank=1. [Accessed 18 February 2011]
23. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009; 127:402-406.
24. Implant B. Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD). http://clinicaltrials.gov/ct2/show/NCT00658619?term=NCT00658619&rank=1
25. Li Y, Tao W, Luo L, et al. CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. PLoS One 2010; 5:e9495.
26. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103:3896-3901. (Pubitemid 43376652)
27. Williams GA, Tao W. A phase II study of encapsulated CNTF secreting cell implant (NT-501) in patients with visual acuity impairment associated with atrophic macular degeneration. Paper presented at: Association for Research in Vision and Ophthalmology; 2009; Ft. Lauderdale, Florida, USA.
28. Francis PJ, Birch DG, Davis JL, et al. A phase 1 open-label, non-comparative study evaluating the safety of a single, unilateral subretinal administration of CNTO2476 (Human Umbilical Tissue-Derived Cells [hUTC]) in advanced retinitis pigmentosa (RP) association for research in vision and ophthalmology; Ft. Lauderdale, Florida, USA; 2010.
29. CNTO2476. A study of the safety and efficacy of CNTO2476 in patients with age-related macular degeneration. http://clinicaltrials.gov/ct2/show/ NCT01226628?term=geographic+atrophy&rank=19 [Accessed March 3 2011]